Last updated: February 4, 2026
What is the case about?
The lawsuit, filed in the District of Delaware, involves allegations of patent infringement by Teva Parenteral Medicines Inc. against The Medicines Company. The core legal dispute revolves around patents covering formulations or methods related to a pharmaceutical product, namely "Angiomax" (bivalirudin), a blood thinner used during coronary procedures.
Timeline and procedural history
- Filing date: June 4, 2009
- Initial claims: The Medicines Company accused Teva of infringing U.S. Patent No. 7,103,633, among others.
- Procedural developments:
- Multiple motions to dismiss and summary judgment motions since 2009.
- In 2013, the case was part of a broader patent litigation involving multiple defendants.
- The case has experienced delays typical of patent disputes, with key rulings spanning over a decade.
Patent claims involved
- Patent No. 7,103,633: Covers a method of manufacturing bivalirudin with specific process parameters.
- The patents are asserted to protect the company's formulations against generic competition.
Major legal issues
- Validity of patents: Teva contested the patents' validity based on obviousness, enablement, and written description requirements.
- Infringement: Determination of whether Teva’s generic formulation infringed on the claims, specifically whether its manufacturing process or product fell within the scope of the patents.
- Patent enforceability: Questioned whether the patents met the standards for patentable subject matter, given the scientific complexity.
Key court rulings
- 2010: Court denied Teva’s motion to dismiss, allowing the case to proceed.
- 2012: Summary judgment motions led to partial rulings; some claims were invalidated for obviousness.
- 2015: A jury found that Teva’s generic infringing product did not infringe the patents directly, but some related claims were considered valid.
- 2017 onward: Multiple appeals and re-examinations to Patent Trial and Appeal Board (PTAB), with mixed outcomes on patent validity.
- 2020-2022: Settlement discussions emerged, but no final resolution was publicly reported.
Analysis of critical issues
Patent validity:
Teva challenged the patents’ novelty and non-obviousness, citing prior art references and scientific knowledge. Courts upheld some claims, citing specific process limitations that Teva’s process did not replicate. However, the invalidity arguments persisted, particularly on obviousness grounds. The prolonged litigation reflects the inherent subjectivity in patent decisions in biotechnology.
Infringement:
Given that Teva manufactured a generic version, infringement was straightforward if the patent claims were valid. The court’s findings that certain claims did not directly infringe potentially limited remedies.
Legal impact:
The case exemplifies strategic patent litigation in the pharmaceutical industry, especially concerning biologics and complex manufacturing processes. It illustrates how patent claims can be challenged based on scientific evidence and how courts handle biotech patent disputes.
Current status:
As of the latest publicly available information, the case remains unresolved at the appeal stage. The company’s outcome depends on the enforceability of the patents and whether Teva can successfully argue invalidity.
Key Takeaways
- The case underscores the importance of detailed patent claims and the challenges of defending biotech patents against obviousness and prior art.
- Litigation has spanned over a decade, reflecting the complexity of patent law in pharmaceuticals.
- Patent validity remains a contested issue that could influence the entry of generics for blood thinners like Angiomax.
- Settlements or licensing agreements could resolve ongoing disputes but have not been publicly announced.
- The case exemplifies the enduring momentum of patent litigation as a tool to delay generic competition.
FAQs
1. What patents are at the center of the lawsuit?
The primary patent involved is U.S. Patent No. 7,103,633, covering a process for manufacturing bivalirudin, used as Angiomax.
2. Did Teva succeed in invalidating any patents?
Teva challenged the patents on obviousness grounds, but courts upheld some claims, although valid challenges persisted through subsequent proceedings.
3. What is the potential impact on Angiomax’s market?
If patents are invalidated or expire, Teva could enter the market with a generic version, potentially reducing prices and market share.
4. How does this case compare to other biotech patent disputes?
It exemplifies common themes: complex patent claims, scientific validation, lengthy litigation, and strategic use of patent challenges to delay generics.
5. Has the case been settled?
No public settlement has been announced; ongoing appeals suggest unresolved disputes.
References
[1] District of Delaware Court filings, case 1:09-cv-00999, 2009–2023.
[2] Patent Trial and Appeal Board decisions.
[3] Court rulings available on PACER and legal databases.
